These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 29769307)
1. Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice. Karlin J; Allen J; Ahmad SF; Hughes G; Sheridan V; Odedra R; Farrington P; Cadogan EB; Riches LC; Garcia-Trinidad A; Thomason AG; Patel B; Vincent J; Lau A; Pike KG; Hunt TA; Sule A; Valerie NCK; Biddlestone-Thorpe L; Kahn J; Beckta JM; Mukhopadhyay N; Barlaam B; Degorce SL; Kettle J; Colclough N; Wilson J; Smith A; Barrett IP; Zheng L; Zhang T; Wang Y; Chen K; Pass M; Durant ST; Valerie K Mol Cancer Ther; 2018 Aug; 17(8):1637-1647. PubMed ID: 29769307 [TBL] [Abstract][Full Text] [Related]
2. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225 [TBL] [Abstract][Full Text] [Related]
3. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Golding SE; Rosenberg E; Valerie N; Hussaini I; Frigerio M; Cockcroft XF; Chong WY; Hummersone M; Rigoreau L; Menear KA; O'Connor MJ; Povirk LF; van Meter T; Valerie K Mol Cancer Ther; 2009 Oct; 8(10):2894-902. PubMed ID: 19808981 [TBL] [Abstract][Full Text] [Related]
4. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Golding SE; Rosenberg E; Adams BR; Wignarajah S; Beckta JM; O'Connor MJ; Valerie K Cell Cycle; 2012 Mar; 11(6):1167-73. PubMed ID: 22370485 [TBL] [Abstract][Full Text] [Related]
5. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Biddlestone-Thorpe L; Sajjad M; Rosenberg E; Beckta JM; Valerie NC; Tokarz M; Adams BR; Wagner AF; Khalil A; Gilfor D; Golding SE; Deb S; Temesi DG; Lau A; O'Connor MJ; Choe KS; Parada LF; Lim SK; Mukhopadhyay ND; Valerie K Clin Cancer Res; 2013 Jun; 19(12):3189-200. PubMed ID: 23620409 [TBL] [Abstract][Full Text] [Related]
6. Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors. Rathi S; Mladek AC; Oh JH; Dragojevic S; Burgenske DM; Zhang W; Talele S; Zhang W; Bakken KK; Carlson BL; Connors MA; He L; Hu Z; Sarkaria JN; Elmquist WF J Pharmacol Exp Ther; 2024 Oct; 391(2):346-360. PubMed ID: 39284626 [TBL] [Abstract][Full Text] [Related]
7. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019. Vecchio D; Daga A; Carra E; Marubbi D; Raso A; Mascelli S; Nozza P; Garrè ML; Pitto F; Ravetti JL; Vagge S; Corvò R; Profumo A; Baio G; Marcello D; Frosina G Int J Cancer; 2015 Mar; 136(6):1445-57. PubMed ID: 25091220 [TBL] [Abstract][Full Text] [Related]
9. ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis. Tew BY; Kalfa AJ; Yang Z; Hurth KM; Simon T; Abnoosian E; Durant ST; Hamerlik P; Salhia B Clin Cancer Res; 2023 Nov; 29(21):4492-4503. PubMed ID: 37585496 [TBL] [Abstract][Full Text] [Related]
10. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095 [TBL] [Abstract][Full Text] [Related]
11. Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts. Scheper J; Hildebrand LS; Faulhaber EM; Deloch L; Gaipl US; Symank J; Fietkau R; Distel LV; Hecht M; Jost T Strahlenther Onkol; 2023 Dec; 199(12):1128-1139. PubMed ID: 36229655 [TBL] [Abstract][Full Text] [Related]
12. The efficacy and toxicity of ATM inhibition in glioblastoma initiating cells-driven tumor models. Frosina G; Marubbi D; Marcello D; Vecchio D; Daga A Crit Rev Oncol Hematol; 2019 Jun; 138():214-222. PubMed ID: 31092378 [TBL] [Abstract][Full Text] [Related]
13. Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent Manner. Palanichamy K; Patel D; Jacob JR; Litzenberg KT; Gordon N; Acus K; Noda SE; Chakravarti A Mol Cancer Ther; 2018 Feb; 17(2):336-346. PubMed ID: 28838997 [TBL] [Abstract][Full Text] [Related]
14. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown Timme CR; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ Mol Cancer Ther; 2018 Jun; 17(6):1207-1216. PubMed ID: 29549168 [TBL] [Abstract][Full Text] [Related]
15. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma. Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506 [TBL] [Abstract][Full Text] [Related]
16. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390. Pike KG; Hunt TA; Barlaam B; Benstead D; Cadogan E; Chen K; Cook CR; Colclough N; Deng C; Durant ST; Eatherton A; Goldberg K; Johnström P; Liu L; Liu Z; Nissink JWM; Pang C; Pass M; Robb GR; Roberts C; Schou M; Steward O; Sykes A; Yan Y; Zhai B; Zheng L J Med Chem; 2024 Feb; 67(4):3090-3111. PubMed ID: 38306388 [TBL] [Abstract][Full Text] [Related]
17. CRISPR Screen of Druggable Targets in Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer. Ran X; Wu BX; Shi M; Song L; Nixon K; Philip V; He HH; Tsao MS; Lok BH Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1308-1314. PubMed ID: 38104868 [TBL] [Abstract][Full Text] [Related]
18. Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas. King AR; Corso CD; Chen EM; Song E; Bongiorni P; Chen Z; Sundaram RK; Bindra RS; Saltzman WM Mol Cancer Ther; 2017 Aug; 16(8):1456-1469. PubMed ID: 28566437 [TBL] [Abstract][Full Text] [Related]
19. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399 [TBL] [Abstract][Full Text] [Related]
20. Activation of the phosphorylation of ATM contributes to radioresistance of glioma stem cells. Zhou W; Sun M; Li GH; Wu YZ; Wang Y; Jin F; Zhang YY; Yang L; Wang DL Oncol Rep; 2013 Oct; 30(4):1793-801. PubMed ID: 23846672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]